Panel discussion on gender equality in science
Available to view on demand. In line with International Women’s Day on the 8th March, Future Science Group held a panel discussion in which members of the scientific community debated the underrepresentation of women in science.
With only ~11% of women
holding senior positions in scientific academia across the EU, the issue of
gender inequality in STEM continues to attract much debate globally. A 2015
study conducted by L'Oréal Foundation, which investigated the public’s perceptions
of scientists, suggested that this disparity may be a result of prejudices
systemic in our society. The survey indicated that 67% of Europeans were of the
opinion that women do not possess the required capabilities needed to access
high-level scientific positions, while in China, 93% were of the belief that
women lacked the abilities to pursue senior science jobs. In spite of this,
over half of the survey’s respondents felt that the evolution of women’s place
in scientific research is shockingly slow and many estimated that women were
far more numerous in science than is actually the case – so what is the cause
for the apparent lack of gender equality in science?
In this panel discussion senior members of the scientific community will be asked to share their thoughts on gender equality and the underrepresentation of women in STEM careers. In addition, panelists will be invited to examine the results of our survey, which canvasses the opinions of the scientific community with regard to this issue. Audience members will also have the opportunity to pose questions to the panel in the live Q&A session.
Why should you tune in?
- Gain an insight into gender equality in STEM
- Learn about what is being done at a political/organizational level to aid women’s rise to senior level scientific positions
- Hear expert opinion on potential causes behind the underrepresentation of women in STEM careers and what is being done to address this
Who may this interest?
- All members of the STEM community, including both academia and industry
- Policymakers engaged in promoting diversity in STEM
Research Associate at University College London, Co-Founder and Director of ScienceGrrl
Ellie Cosgrave is an Engineer and Research Associate at University College London’s Department of Science Technology Engineering and Public Policy (UCL STEaPP). She is also Co-Founder and Director of ScienceGrrl – a national network that supports women in science and engineering careers. Ellie’s academic work explores the future of cities, with a particular focus on how digital technologies are transforming urban spaces and challenging existing systems of governance. As part of her role at ScienceGrrl, Ellie shapes the strategic direction of the organization through close engagement with the organization’s membership. She works with schools and science museums to develop outreach content for work with young people. She also plays a role in advising national policy on girls’ access to STEM careers and is often invited to attend sector roundtable discussions and government events. As part of her policy advice, Ellie co-authored the report ‘Through Both Eyes: the case for a gender lens in STEM’, which highlights the invisible hurdles affecting young girls and lays out policy recommendations for the STEM sector. Ellie is often asked to present at careers fairs, STEM industry events, feminist conferences and appear on radio and TV news programmes.
Group leader, Cellular & Systems Neurobiology, Center for Genomic Regulation
Dr Dierssen’s research builds on multilevel exploration of neural
networks and dynamical models to provide insight into the integrative
principles in brain cognitive systems, predominantly using genetically
modified mouse models of intellectual disability and other cognition
disorders. The overall goal of her research is understanding how
putative candidate genes for human complex genetic diseases impair the
neuronal connectivity with consequences on brain cognitive systems. She
is a world expert in the field and has received several recognitions for
her work (Ramón Trias Fargas, Jaime Blanco or Sisley-Lejeune Awards).
Dr Dierssen is past President of the Spanish Society of Neuroscience,
and of the International Behavioral and Neural Genetics Society, member
of the Executive Committee of the Federation of European Neurosciences
Societies, founder member and Secretary General of the Trisomy 21
Research Society, The European DANA and has been elected member of the
Principal Scientist, Merck
Ying graduated from Peking University in China with a BS in Chemistry,
and obtained a PhD from Ochanomizu University in Japan. After completing
a joint postdoc program at Eli Lilly and IUPUI, and briefly working at
Pharm-Eco, she joined Merck in 1996 as a Senior Research Chemist and has
been involved in a wide variety of computer aided drug design programs
across therapeutic areas. Her most rewarding experience has been
contributing to the discovery of DPP-4 inhibitors for the treatment of
type II diabetes as a key inventor. Ying has over 70 publications and
Michael A Reilly
Director Quantitative Pharmacology, GlaxoSmithKline
Mike has over 20 years of experience as a researcher in drug discovery
within big Pharma. This includes 12 years working at Merck in the UK and
US, exploring new chemical entities for the treatment of a range of
disorders from Neuroscience to Oncology. For the last eight years he has
led a team of drug metabolism and pharmacokinetic scientists who have
been developing treatments for diseases in the immuno inflammatory
space. Most recently his role has expanded to include leading a group of
in vivo pharmacologists as well.
Susan L Solomon
CEO and Co-Founder, The New York Stem Cell Foundation (NYSCF)
Susan L Solomon is Founder and Chief Executive Officer of The New York Stem Cell Foundation (NYSCF) Research Institute, the world’s leading non-profit research institute dedicated to translating cutting-edge stem cell research into clinical breakthroughs. Privately funded, NYSCF is unconstrained and therefore unique in its ability to expedite the most promising stem cell research both at its own independent laboratory employing 45 full-time scientists and through its collaborations with more than 50 academic, philanthropic, and corporate institutions around the globe.
Sandra M Swain, MD, FACP, FASCO
Medical Director, Washington Cancer Institute, MedStar Washington Hospital Center, Professor, Georgetown University
Sandra M Swain, MD, FACP, FASCO is the Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center in Washington, DC. She is also a Professor of Medicine at Georgetown University and Adjunct Professor of Medicine at Uniformed Services University of the Health Sciences. Previously, she served at the National Institutes of Health as the Deputy Branch Chief for the Medicine Branch of the Center for Cancer Research at the National Cancer Institute (NCI) with tenure as a Principal Investigator. At the NIH, she was also the Head of the Breast Cancer Section, and Chief of the Cancer Therapeutics Branch. She graduated with a Bachelor of Arts (BA) in Chemistry from the University of North Carolina in 1975 and earned her Doctor of Medicine (MD) from the University of Florida in Gainesville in 1980. She completed a residency in Internal Medicine at Vanderbilt University in 1983 followed by a fellowship in Medical Oncology at the NCI in 1986.
Swain’s research interests include translational research and clinical trials focused on metastatic and inflammatory breast cancer, adjuvant therapy for breast cancer, cardiotoxicity, and health care disparities. Her research has received funding from the National Institutes of Health, Susan G. Komen Foundation, Breast Cancer Research Foundation, and the Avon Foundation. She has published over 250 articles and is internationally recognized as a leader in the field breast cancer research and treatment. Moreover, Swain has received numerous awards and recognitions for her work, including the Susan G. Komen Award of Distinction for Community Service in 2012. She is also a recipient of the National Institutes of Health Merit Award, as well as a two-time recipient of the National Cancer Institute Mentor of Merit Award. She received the Claude Jacquillat Award for Clinical Cancer Research in 2012.
Swain served as President of the American Society of Clinical Oncology (ASCO) from 2013-14. She is currently a member of the Conquer Cancer Foundation Board of Directors and was previously a member of the ASCO Board of Directors. She sits on the Board of Directors for the MedStar Washington Hospital Center and the MedStar Washington Hospital Center Foundation. She has actively contributed to the National Surgical Adjuvant Breast and Bowel Project for over 25 years and is an active member of the NRG Breast Committee. She is also a member of the American Association of Cancer Research.
For a full list of other webinars available on RegMedNet please see here.